Prime editing, known for its ability to introduce targeted insertions, deletions, or base conversions within the genome, is typically restricted to short DNA segments. Similarly, Gibson assembly is a laboratory method that allows the seamless joining of multiple DNA fragments in a controlled, single-reaction setting. By ingeniously combining these methods, prime assembly expands the horizon of genomic editing to unprecedented lengths, potentially analogous to swapping an entire paragraph or chapter in a vast genetic manuscript rather than just a single letter or word.

Erik Sontheimer, PhD, Pillar Chair in Biomedical Research and a professor specializing in RNA therapeutics, explains that existing gene editing technologies—including prime editing, base editing, and CRISPR-Cas9—are largely limited to swapping out small snippets of genetic code, comparable to editing individual characters in text. The novel prime assembly system circumvents these constraints, furnishing the capability to insert gene-length sequences efficiently and accurately, thereby addressing genetic disorders associated with large mutations or clusters of mutations dispersed across genes.

Published in the prestigious journal Nature, this research embodies a collaborative effort involving notable experts such as Wen Xue, PhD, Professor of RNA Therapeutics, Scot A. Wolfe, PhD, and several dedicated students and postdoctoral fellows from the UMass Chan community. Their collective insights and technological advancements represent a significant leap forward in precisely correcting vast genomic defects with potential clinical applications in gene therapy.

One of the primary challenges in treating genetic diseases stems from the myriad mutations present within individual genes, necessitating multiple, mutation-specific therapeutic interventions. Current technologies falter when faced with this complexity, as they excel only at small edits and require tailored approaches for each mutation, which is neither efficient nor practical. Prime assembly resolves this by enabling scientists to insert DNA insertions as long as 11,000 base pairs, encompassing entire gene sequences and thereby simplifying therapeutic design.

Technically, prime assembly employs a twin prime editing approach to generate programmable single-stranded DNA flaps at the target genomic locus. These flaps precisely anneal to complementary regions on the donor DNA, facilitating seamless integration without creating double-strand breaks (DSBs), which are prone to causing unpredictable mutations or deletions due to error-prone cellular repair mechanisms. Instead, prime assembly induces single-strand nicks, a gentler approach that minimizes deleterious consequences on genome integrity and cellular viability.

The elegance of this technology lies not only in the scale of DNA it can incorporate but also in the streamlined nature of its process compared to other large-sequence insertion methods. Traditional gene editing techniques that enable sizable insertions often involve complex viral delivery systems or induce more damaging genomic interventions. Prime assembly’s methodology bypasses these pitfalls, making it a biotechnological breakthrough with promising implications for both research and eventual clinical translation.

Another remarkable advantage of prime assembly is its effectiveness in nondividing cells, such as neurons. Many current gene editing modalities are optimized for dividing cells, limiting their utility in treating neurological disorders or other conditions involving quiescent cells. By operating efficiently within cells that do not frequently divide, prime assembly opens avenues for addressing a broader array of diseases previously deemed inaccessible to gene replacement therapies.

Moreover, prime assembly’s intrinsic capacity to join multiple DNA fragments mirrors the functionality of Gibson assembly in vitro but accomplishes it within the genomic context. This ability to stitch together several DNA strands endogenously broadens possibilities for creating more complex genetic modifications, including the insertion of synthetic genes, regulatory sequences, or entire genomic loci, which could revolutionize synthetic biology and therapeutic gene design.

Looking ahead, the research team aims to unravel the precise endogenous cellular mechanisms that prime assembly engages to mediate DNA joining within the genome. A deeper understanding of these native processes may illuminate how to further enhance the efficiency and safety of prime assembly, while also guiding its adaptation to diverse cell types and organisms. Parallelly, preclinical studies in animal models are poised to evaluate the therapeutic potentials and biosafety of this technology, fostering progress toward clinical applications.

The development of prime assembly represents a critical advance toward the overarching goal of gene therapy: to create versatile, efficient, and broadly applicable tools capable of repairing the vast spectrum of genetic mutations that underlie human disease. By enabling the insertion of large DNA sequences with precision and minimal genomic disruption, prime assembly stands to transform the landscape of genetic medicine, offering hope for patients with complex genetic disorders.

UMass Chan Medical School, home to this breakthrough research, is a hub of innovation, integrating cutting-edge biomedical science with translational initiatives aimed at addressing global health challenges. Their interdisciplinary approach combines expertise in RNA therapeutics, molecular biology, and genetic engineering, nurturing an environment where transformative technologies like prime assembly can emerge and thrive.

As the field of genome engineering continues to expand rapidly, prime assembly sets a new benchmark for what is achievable in editing the human genome. Its convergence of prime editing’s precision and Gibson assembly’s assembly prowess encapsulates the future of gene therapy: precise, scalable, and capable of tackling genetic diseases at an unprecedented scale and complexity.

The implications of this technology extend beyond gene therapy alone, impacting research areas such as functional genomics, synthetic biology, and regenerative medicine. With its ability to rewrite extensive sections of the genome, prime assembly empowers researchers to probe genetic functions in greater detail and devise innovative strategies to counteract disease.

In conclusion, the advent of prime assembly redefines the frontier of genomic editing, heralding a new era where entire genes, not just snippets, can be seamlessly edited, inserted, and replaced. This landmark innovation aligns with the vision of personalized medicine, promising tailored, effective treatments for patients burdened by the complexity of genetic disease.

Subject of Research: Cells

Article Title: Prime assembly with linear DNA donors enables large genomic insertions

News Publication Date: April 29, 2026

Web References:
https://www.nature.com/articles/s41586-026-10460-4

References:
Sontheimer, E., Xue, W., et al. (2026). Prime assembly with linear DNA donors enables large genomic insertions. Nature. DOI: 10.1038/s41586-026-10460-4.

Image Credits: Bryan Goodchild, UMass Chan Medical School

Keywords: Gene editing, Gene therapy, Genetics, Genetic engineering, Gene delivery, Genomics, Human genetics, Molecular genetics, Molecular biology, Nucleic acids

Cilia, microtubule-based organelles extending from nearly all mammalian cells, perform an array of essential roles ranging from motility and sensory functions to the transduction of biochemical signals. Malfunction or structural aberrations in cilia culminate in ciliopathies, a heterogeneous group of multisystemic disorders. Patients with mutations in the TMEM67 gene often suffer from the most severe ciliopathies, including Meckel-Gruber syndrome, characterized by embryonic lethality and profound developmental anomalies. Until now, the mechanistic details of TMEM67’s involvement in these pathologies remained obscure.

The UMass Chan team discovered that TMEM67 is not a monolithic protein entity; rather, it undergoes a highly specific proteolytic cleavage by the enzyme ADAMTS9 at an evolutionarily conserved site. This cleavage event results in two isoforms with separate and indispensable functions. The first isoform localizes to the ciliary transition zone, a strategically important gating region positioned at the base of the cilium. This gate functions as a molecular checkpoint that regulates the trafficking of proteins and lipids, effectively maintaining the biochemical compartmentalization of the ciliary compartment which is critical for cilia stability and signaling.

Failure to execute the cleavage of TMEM67 leads to the retention of a noncleaved isoform that disrupts cilia gating mechanisms. In such mutated scenarios, cilia frequently exhibit dysmorphic appearances such as abnormal ballooning or satellite-dish-like expansions, reflecting defective structural integrity and impaired signaling capacity. This dysfunction is a hallmark of syndromic ciliopathies, wherein compromised ciliary dynamics translate to broad developmental and physiological defects observable in patients.

In parallel, the uncut TMEM67 isoform plays a pivotal role in facilitating noncanonical Wnt signaling. The Wnt signaling pathway is a highly conserved cellular communication system that regulates numerous developmental processes, including cell proliferation, differentiation, and polarity. The study reveals that the noncleaved TMEM67 isoform acts as a critical transducer within this pathway, emphasizing TMEM67’s dual-functionality—balancing structural roles in ciliogenesis and molecular control in cell signaling.

Employing state-of-the-art proteomics and mass spectrometry technologies, the researchers pinpointed the exact cleavage site conserved across diverse species including murine models, the nematode Caenorhabditis elegans, and humans. This interspecies conservation underscores the fundamental evolutionary importance of TMEM67’s cleavage and its associated bifunctional roles. Such evolutionary preservation suggests that perturbations in this cleavage mechanism have dire developmental consequences that have been negatively selected throughout evolution.

This research also highlights the broader biological principle of protein multifunctionality through regulated proteolysis. By generating isoforms with distinct cellular destinations and functions, cells achieve regulatory complexity and precision indispensable for organismal development and homeostasis. Specifically, the duality of TMEM67 allows it to act simultaneously as a structural scaffold at the cilium base and as a signaling mediator within the Wnt pathways.

The clinical implications of these findings are profound. Ciliopathies represent a challenging class of diseases for which no targeted therapies currently exist. Understanding the dual roles of TMEM67 and the molecular nuances of its cleavage provides a concrete molecular target. Future drug discovery efforts may focus on modulating TMEM67 cleavage or mimicking the function of its isoforms to restore normal ciliary function and cell signaling in affected patients.

The interdisciplinary collaboration among developmental biologists, geneticists, and cell biologists at UMass Chan Medical School further underscores the power of integrating proteomics, genetics, and model organism research to dissect complex biological questions. Postdoctoral fellow Manu Ahmed and PhD candidate Sydney Fischer were instrumental contributors to expanding the mechanistic framework of this investigation.

Moreover, the study advances knowledge on the interplay between ciliary biology and signal transduction pathways. Cilia have long been appreciated for their sensory roles, but this research emphasizes how their assembly and signaling capacities are finely coordinated through post-translational processing of critical proteins like TMEM67. The insights extend beyond ciliopathies, potentially informing the pathophysiology of other disorders involving Wnt signaling and cellular compartmentalization.

Looking forward, the team plans to dissect the independent mechanisms by which each TMEM67 isoform exerts its effects and to explore potential compensatory pathways that may be recruited when normal cleavage is disrupted. These endeavors will pave the way for novel intervention strategies aimed at mitigating the severe developmental defects associated with TMEM67 mutations.

This landmark study published in Nature Communications not only elucidates a fundamental biological process but also brings hope to families affected by ciliopathies. It exemplifies how detailed molecular dissections can unravel disease mechanisms and guide the development of next-generation therapeutics in rare genetic disorders with devastating clinical outcomes.

Subject of Research: Animals

Article Title: Cleavage of the Meckel-Gruber syndrome protein TMEM67 by ADAMTS9 uncouples Wnt signaling and ciliogenesis

News Publication Date: 28-May-2025

Web References:

• Nature Communications Article
• DOI: 10.1038/s41467-025-60294-3

Image Credits: Photo by Bryan Goodchild, UMass Chan Medical School

Keywords:
Cilia, Primary cilia, Cell biology, Genetic disorders